FindTrial
Sign In

non-specific immune-modulator therapy

PROCEDURE5 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI), Eastern Cooperative Oncology Group, The Cleveland Clinic, Favrille, University of Nebraska

Conditions

Adult Acute Erythroid LeukemiaAdult Acute Monoblastic and Acute Monocytic LeukemiaAdult Acute Myeloid LeukemiaChronic Myeloproliferative DisordersKidney CancerLeukemiaLymphomaMyelodysplastic/Myeloproliferative Diseases

Phase 2

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
TerminatedNCT00066417
National Heart, Lung, and Blood Institute (NHLBI)Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
End: 2007-01-31Target: 51Updated: 2013-05-01
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
WithdrawnNCT00101140
Eastern Cooperative Oncology GroupAdult Acute Erythroid Leukemia, Adult Acute Monoblastic and Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia
Updated: 2017-10-19
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
WithdrawnNCT00112879
The Cleveland ClinicRefractory Plasma Cell Neoplasm, Stage III Multiple Myeloma, Stage II Multiple Myeloma +1
Updated: 2013-07-10
Talabostat in Treating Patients With Metastatic Kidney Cancer
WithdrawnNCT00489710
University of NebraskaKidney Cancer
Start: 2006-12-31End: 2007-05-30Updated: 2023-08-22

Phase 3

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
SuspendedNCT00324831
FavrilleLymphoma
Target: 480Updated: 2013-12-18